Is Welcure Drugs & Pharmaceuticals Ltd (524661) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Welcure Drugs & Pharmaceuticals Ltd is a average quality company .

Is Welcure Drugs & Pharmaceuticals Ltd (524661) undervalued or overvalued?

The key valuation ratios of Welcure Drugs & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Welcure Drugs & Pharmaceuticals Ltd (524661) share price return in the past 10 years?

Welcure Drugs & Pharmaceuticals Ltd share price has appreciated 9.4% annually (CAGR) over the past ten years.

Is Welcure Drugs & Pharmaceuticals Ltd (524661) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Welcure Drugs & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Welcure Drugs & Pharmaceuticals Ltd (524661)?

Company share prices are keep on changing according to the market conditions. The current trading price of Welcure Drugs & Pharmaceuticals Ltd (524661) on 17-Apr-2026 16:59:59 at 16:59 is 0.32.

What is the P/E ratio of Welcure Drugs & Pharmaceuticals?

The latest standalone P/E ratio of Welcure Drugs & Pharmaceuticals as of 17-Apr-2026 is 1.15.

What is the P/B ratio of Welcure Drugs & Pharmaceuticals Ltd (524661)?

The latest standalone P/B ratio of Welcure Drugs & Pharmaceuticals Ltd (524661) as of 17-Apr-2026 is 0.28.

What is the 52-week high and low of Welcure Drugs & Pharmaceuticals Ltd (524661)?

The 52-week high of Welcure Drugs & Pharmaceuticals Ltd (524661) is Rs. 1.44 and the 52-week low is Rs. 0.23.

Welcure Drugs & Pharmaceuticals Ltd (524661) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Welcure Drugs & Pharmaceuticals Ltd (524661)
Brand: Welcure Drugs & Pharmaceuticals

Welcure Drugs & Pharmaceuticals Ltd (524661) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Key Metrics

Market Cap

₹41 Cr.

P/E Ratio

1.15

Price to Book (P/B)

0.28

Price to Sales (P/S)

0.11

EV/EBITDA

3.52

Return on Capital Employed (ROCE)

2.53%

Current Price

₹0.3

Return on Equity (ROE)

4.18%

Return on Assets (ROA)

1.62%

Operating Profit Margin

3.9%

Net Profit Margin

8.84%

Gross Profit Margin

11.4%

Book Value per Share

₹1.2

Sales Growth (YoY)

NA%

Sales Growth (3 Years)

506.58%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

264.68%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹0 / 1

Net Profit Growth (3 Years)

-90.27%

Dividend Yield

0.00%

Promoter Holding

0.00%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Welcure Drugs & Pharmaceuticals Ltd?

Welcure Drugs & Pharmaceuticals Ltd revenue growth is 0% for FY-2025 , which is below its 5 year CAGR of 214.3% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Welcure Drugs & Pharmaceuticals Ltd?

Promoters hold 0.00% of the Welcure Drugs & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Welcure Drugs & Pharmaceuticals Ltd vs industry peers?

Welcure Drugs & Pharmaceuticals Ltd revenue CAGR is 214.33% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Welcure Drugs & Pharmaceuticals Ltd belong to?

Welcure Drugs & Pharmaceuticals Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.

Q.1 Stock return of Welcure Drugs & Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 9.4% based on the current price.

DeciZen - make an informed investing decision on Welcure Drugs&Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Welcure Drugs & Pharmaceuticals stock performance

Key Ratios

Is Welcure Drugs & Pharmaceuticals Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0%	108.9%	-65.5%	18.2%	-48.9%	131.9%	29.1%	12.7%	-12.2%	2.5%	-
Value Creation Index ⓘ	NA	6.8	-5.7	0.3	-4.5	8.4	1.1	-0.1	-1.9	-0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0	24.6	387
Sales YoY Gr.	-	-10%	-44.4%	60%	0%	62.5%	-15.4%	-100%	NA	NA	-
Adj EPS ⓘ	0	0	-0	0	-0	0	0	0	-0	0	0.3
YoY Gr.	-	-100%	NA	NA	NA	NA	NA	NA	-200%	NA	-
BVPS (₹) ⓘ	0	0	0	0	0	0	0	0.1	0.1	0.8	1.2
Adj Net Profit ⓘ	0.1	0	-0	0	-0	0.1	0	0.1	-0.2	2.2	36
Cash Flow from Ops. ⓘ	-0.1	0	-0	0	-0	0	0	0.1	-0.1	-222	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	-0.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	84.3%	214.3%	506.6%	NA
Adj EPS ⓘ	8%	NA	NA	NA
BVPSⓘ	NA	NA	336.2%	822.2%
Share Price	9.4%	13.5%	-3.9%	-57.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-274.3	108.6	-65.8	17.8	-49.5	131.7	29	11.4	-12	4.2	28.7
Op. Profit Mgn % ⓘ	32.4	30.9	-41	2.9	-11.6	41.3	22.5	0	0	3.9	11.2
Net Profit Mgn % ⓘ	85.6	30.8	-38.8	4.9	-11.4	41.4	22.5	0	0	8.8	9.3
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	1.2	-
Working Cap Days ⓘ	28	60	109	59	76	61	98	0	0	1,993	381
Cash Conv. Cycle ⓘ	0	0	0	0	0	0	0	0	0	1,205	209

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0.3	-0
TTM Sales (₹ Cr.)	387	0.4
BVPS (₹) ⓘ	1.2	0
Reserves (₹ Cr.) ⓘ	23	-13
P/BV ⓘ	0.28	0.00
PE ⓘ	1.15	0.00

From the Market
52 Week Low / High (₹)	0.23 / 1.44
All Time Low / High (₹)	0.03 / 3.64
Market Cap (₹ Cr.)	40.8
Equity (₹ Cr.)	123.6
Face Value (₹)	1
Industry PE ⓘ	25.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Welcure Drugs&Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0.10	0.09	0.05	0.08	0.08	0.13	0.11	0	0	24.55
Operating Expenses ⓘ +	0.07	0.06	0.07	0.08	0.09	0.08	0.08	0.13	0.23	23.58
Manufacturing Costs	0	0	0	0	0	0	0	0	0	0.01
Material Costs	0	0	0	0	0	0	0	0	0	20.50
Employee Cost	0	0	0	0	0	0	0	0.03	0.08	0.10
Other Costs ⓘ	0.07	0.06	0.07	0.08	0.09	0.08	0.08	0.10	0.15	2.97
Operating Profit ⓘ	0.03	0.03	-0.02	0	-0.01	0.06	0.02	-0.13	-0.23	0.97
Operating Profit Margin (%)	32.4%	30.9%	-41.0%	2.9%	-11.6%	41.3%	22.5%	-	-	3.9%
Other Income ⓘ +	0.05	0	0	0	0	0	0	0.24	0.09	1.91
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	0	0	0	0	0	0.09
Depreciation ⓘ	0	0	0	0	0	0	0	0	0.04	0.01
Profit Before Tax ⓘ	0.09	0.03	-0.02	0	-0.01	0.06	0.02	0.10	-0.17	2.78
Tax ⓘ	0	0	0	0	0	0	0	0	0	0.61
Profit After Tax	0.09	0.03	-0.02	0	-0.01	0.06	0.02	0.10	-0.17	2.17
PAT Margin (%)	85.6%	30.8%	-38.8%	4.9%	-11.4%	41.4%	22.5%	-	-	8.8%
Adjusted EPS (₹)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.0	0.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	0.01	0.04	0.02	0.02	0.01	0.07	0.09	1.52	1.34	102.51
Share Capital ⓘ	12.12	12.12	12.12	12.12	12.12	12.12	12.12	13.44	13.44	112.44
Reserves ⓘ	-12.11	-12.08	-12.10	-12.09	-12.10	-12.05	-12.03	-11.92	-12.10	-9.93
Debt +	0	0	0	0	0	0	0	0	0	123.20
Long Term Debt	0	0	0	0	0	0	0	0	0	123.20
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0	0	0	0	0	0	0	2.90
Others Liabilities ⓘ	0	0	0	0.01	0.01	0	0	0.01	0.03	38.37
Total Liabilities ⓘ	0.02	0.04	0.02	0.03	0.02	0.07	0.10	1.53	1.37	266.98
Fixed Assets
Net Fixed Assets ⓘ +	0	0	0	0	0	0	0	0.06	0.02	0.03
Gross Block	0	0	0	0	0	0	0	0.06	0.06	0.08
Accumulated Depreciation	0	0	0	0	0	0	0	0	0.04	0.05
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0.17	0	0
Inventories	0	0	0	0	0	0	0	0	0	143.52
Trade Receivables	0	0	0	0	0	0	0	0	0	18.95
Cash Equivalents	0.01	0.02	0.01	0.01	0.01	0.05	0.07	0	0.02	0.13
Others Assets ⓘ	0.01	0.02	0.01	0.01	0.02	0.03	0.03	1.31	1.33	104.35
Total Assets ⓘ	0.02	0.04	0.02	0.03	0.02	0.07	0.10	1.53	1.37	266.98

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.05	0.02	-0.01	0	-0.01	0.04	0.02	0.11	-0.13	-222.03
PBT ⓘ	0.09	0.03	-0.02	0	-0.01	0.06	0.02	0.10	-0.17	2.78
Adjustment ⓘ	-0	0	0	0	0	0	0	0	0.04	0.01
Changes in Working Capital ⓘ	-0.13	-0.01	0.01	-0	-0	-0.01	-0.01	0.01	0.01	-224.82
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	0.03	0	0	0	0	0	0	0	0.17	-0.06
Capex	0	0	0	0	0	0	0	0	0	-0.02
Net Investments	0	0	0	0	0	0	0	0	0.17	0
Others ⓘ	0.03	0	0	0	0	0	0	0	0	-0.05
Cash Flow From Financing Activity ⓘ +	0	0	0	0	0	0	0	-0.17	-0.02	222.20
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	1.32	0	99
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	123.20
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	-1.49	-0.02	0
Net Cash Flow ⓘ	-0.02	0.02	-0.01	0	-0.01	0.04	0.02	-0.07	0.02	0.11

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0	108.61	-65.8	17.83	-49.46	131.74	29.03	12.69	-12.24	4.18
ROCE (%)	0	108.91	-65.46	18.22	-48.94	131.94	29.12	12.69	-12.24	2.53
Asset Turnover Ratio	2.66	3.07	1.51	2.99	3.03	2.73	1.24	0	0	0.18
PAT to CFO Conversion(x)	-0.56	0.67	N/A	N/A	N/A	0.67	1	1.1	N/A	-102.32
Working Capital Days
Receivable Days	0	0	0	0	0	0	0	0	0	282
Inventory Days	0	0	0	0	0	0	0	0	0	2,134
Payable Days	0	0	0	0	0	0	0	0	0	52

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Welcure Drugs & Pharmaceuticals Ltd FAQs

The current trading price of Welcure Drugs&Pharma on 17-Apr-2026 16:59 is ₹0.32.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Welcure Drugs&Pharma stood at ₹40.79 Cr

The latest P/E ratio of Welcure Drugs&Pharma as of 16-Apr-2026 is 1.15.

The latest P/B ratio of Welcure Drugs&Pharma as of 16-Apr-2026 is 0.28.

The 52-week high of Welcure Drugs&Pharma is ₹1.44 and the 52-week low is ₹0.23.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Welcure Drugs&Pharma is ₹387 ( Cr.) .

About Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs & Pharmaceuticals Ltd. (WDPL) was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.

Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation.

Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base.

In March 2000 WDPL entered into a five-year agreement with Bihar Drugs and Chemicals Ltd (BDCL), a subsidiary of Bihar State Pharmaceutical and Chemical Development Corporation Ltd, for manufacturing various pharmaceutical pro ducts (both generic as well as branded) for the latter on loan licence basis. WDPL manufactures the drugs in tablet, capsule and syrup form at its facilities situated in Bhiwadi (Rajasthan).

The Companyâ€™s principal activity is to manufacture pharmaceutical products. The products of the Company include tablets, capsules, liquid orals and dry syrups.

Product range of the company includes:

Welcure manufactures a large variety of pharmaceutical formulations, covering almost all ailments, about 250 in numbers. Some of our known products include:

Brucure
Diclo-plus, Dimcinplus
Nimesulide
Nimagyltd (tongue dissolvent)
Ibucure & Relaxon Forte
Coldrest, Alert10004 Coldhistex
Cezen & Cezen Forte, Cezen CD
Kuffwel
X-Dryl, X-Dryl Forte
Renact DM
Renact DC
Diaroban
Welcee (Chewable Tab.)
Calbiplex
Wormicide
X-Clox
Weloxy-L
Welquin
Nortin, Cipcin-TNZ
Sarvo
B-Rest
Lopcure
Rifampicin, Ethambutol, Rifa-Z
Weloxy-P,Amicure-P
Norkid

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Welcure Drugs & Pharmaceuticals Ltd (524661) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Welcure Drugs&Pharma Share Price